Long-term Effect of a 3-month Supplementation With Holo-BLG on House Dust Mite Induced Allergic Rhinoconjunctivitis

Inclusion Criteria: * Participation in the predecessor study including complete intake of the holo-BLG lozenge for 3 months; inclusion in the final analysis set of the predecessor study * patients with allergic rhinoconjunctivitis caused by house dust mites of any gender, aged 18-65 years * Verbal and written informed consent Exclusion Criteria: * Persons \<18 years * lack of verbal and written consent * persons who do not speak German * seriously ill persons * Persons with immunosuppressive medication such as systemic corticosteroids, cyclosporine * Pregnancy and breastfeeding * psychiatric illness * Persons who have received or have started sublingual or subcutaneous immunotherapy (SLIT/SCIT) against house dust mites in the last 2 years before screening * Contraindications and/or history of adrenaline intolerance and/or emergency medication. * Concurrent use of anti-allergic medications and/or inadequate washout period of these anti-allergic medications prior to the selection process and exposure in the exposure chamber * Use of an investigational drug 30 days/5 half-lives of the drug (whichever is longer) prior to screening * Use of certain drugs prior to V5: Systemic corticosteroids within 3 weeks; Topical nasal corticosteroids within 2 weeks; Chromones within 7 days; Antihistamines within 72h; Antibiotics within 3 months; Pro-, Pre- and Synbiotics 1 month